stockrow
Friday 6 November 2026
Export RLAY’s income statement to Excel — free account
Relay Therapeutics, Inc.
RLAY Healthcare Biotechnology
Relay Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $15.4 million, up 53.4% from fiscal 2024.
- Revenue
- −95.4%
- EPS
- +13.3%
- Free cash flow
- +2.13%
Quarter to September 2026, against a year earlier
18.44
1.44
+8.47%
Follow RLAY
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
— | — | 4 | — |
+8 more TTM periods Free account |
| (41.16%) | (36.77%) | (40.01%) | (41.12%) | ||
| (37.37%) | (33.72%) | (36.39%) | (37.05%) | ||
ROIC |
0.00% | 0.00% | (157,022.78%) | (1,508.62%) | |
Return on Tangible Assets |
(36.42%) | (32.57%) | (43.29%) | (49.87%) | |
Average Days of Receivables |
— | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.98) | (1.05) | (1.19) | (1.37) | |
Free Cash Flow |
(214.02) | (212.20) | (213.36) | (235.86) | |
Capital Expenditures |
— | — | — | (0.41) | |
| Other line items | |||||
Cash ROIC |
(12.83%) | (11.78%) | (16.61%) | (21.03%) | |
Accounts Receivable Turnover |
— | 0.00 | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 2,455.31% | 1,406.36% | 1,030.61% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 454.04% | 266.95% | 223.60% | |
Share Based Compensation of Revenue |
0.00% | 438.15% | 292.19% | 246.11% | |
Operating CF/Net income |
0.73 | 0.74 | 0.78 | 0.85 | |
Depreciation/Fixed assets |
(2.43) | (1.34) | 0.83 | 0.53 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | (0.45) | |
Revenue per Share |
0.00 | 0.05 | 0.10 | 0.15 | |
Operating CF per Share |
(0.98) | (1.05) | (1.19) | (1.37) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
— | 0.00 | 0.00 | 0.02 |
Columns are period end dates · fundamentals updated 6 Nov 2026